Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases

International Journal of Urology

Volumn 9, Issue 9, 2002, Pages 509-514

  Zhang, Xianghua ^a   Yamashita, Motoki ^a   Uetsuki, Hirotsugu ^a   Kakehi, Yoshiyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Matrix metalloproteinase; Microvessel density; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; GELATINASE A; GELATINASE B; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A; CD31 ANTIGEN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION; ANGIOGENESIS; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DENSITY; DISEASE ASSOCIATION; EVALUATION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL ANALYSIS; TISSUE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036440693     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00511.x     Document Type: Article

References (32)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995; 1: 27-31.
2. Auerbach W, Auerbach R. Angiogenesis inhibition: A review. Pharmacol. Ther. 1994; 63: 265-311.
3. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: Models and modulators. Int. Rev. Cytol. 1995; 159: 113-60.
4. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
5. Ferrara N, Davis ST. The biology of vascular endothelial growth factor. Endocr. Rev. 1997; 18: 4-25.
6. Lewis CE, Leek R, Harris A, McGee JO. Cytokine regulation of angiogenesis in breast cancer: The role of tumor-associated macrophages. J. Leukoc. Biol. 1995; 57: 747-51.
7. Liotta LA, Thorgeirsson UP, Garbisa S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev. 1982; 1: 277-88.
8. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 1997; 89: 1260-70.
9. Mancilla JR, Stanley RJ, Blath RA. Papillary renal cell carcinoma: A clinical, radiologic, and pathologic study of 34 cases. Cancer 1976; 38: 2469-80.
10. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992; 3: 65-71.
11. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol 1995; 147: 9-19.
12. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas, carcinomas). Pathol. Res. Pract. 1986; 181: 125-43.
13. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors 5th Edn. John Wiley, New York, 1997.
14. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 1982; 6: 655-63.
15. Zhang X, Kong C, Takenaka I. Evaluation of cell proliferation, apoptosis, and angiogenesis in transitional cell carcinoma of the renal pelvis and ureter. Urology 2001; 57: 981-5.
16. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: Lack of prognostic significance. Urology 1995; 46: 27-30.
17. Kohler HH, Barth PJ, Siebel A, Gerharz EW, Bittinger A. Quantitative assessment of vascular surface density in renal cell carcinomas. Br. J. Urol. 1996; 77: 650-4.
18. Nativ O, Sabo E, Reiss A, Wald M, Madjar S, Moskovitz B. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology 1998; 51: 693-6.
19. Yoshino S, Kato M, Okada K. Evaluation of the prognostic significance of microvessel count and tumor size in renal cell carcinoma. Int. J. Urol. 1998; 5: 119-23.
20. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 2000; 163: 343-7.
21. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J. Urol. 1998; 160: 1914-8.
22. Tomisawa M, Tokunaga T, Oshika Y et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer 1999; 35: 133-7.
23. Walther MM, Kleiner DE, Lubensky IA et al. Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology 1997; 50: 295-301.
24. Nicol D, Hii SI, Walsh M et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol. 1997; 157: 1482-6.
25. Gohji K, Fujimoto N, Hara I et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer 1998; 79: 96-101.
26. Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J. Urol. 1999; 161: 1359-63.
27. Gohji K, Nomi M, Hara I, Arakawa S, Kamidono S. Influence of cytokines and growth factors on matrix metalloproteinase-2 production and invasion of human renal cancer. Urol. Res. 1998; 26: 33-7.
28. Horie S, Aruga S, Kawamata H, Okui N, Kakizoe T, Kitamura T. Biological role of HGF/MET pathway in renal cell carcinoma. J. Urol. 1999; 161: 990-7.
29. Kitadai Y, Haruma K, Tokutomi T et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res. 1998; 4: 2195-200.
30. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55: 3964-8.
31. Lein M, Jung K, Laube C et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int. J. Cancer 2000; 85: 801-4.
32. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer Res. 2001; 7: 3113-9.